2026

Register now for the key partnering and investment summit for global leaders in CNS neuroscience drug discovery and development.

Feb - 24-26-2026

Amsterdam - The Netherlands

2026 EARLY REGISTRATION ENDS OCTOBER 31

Profy Countdown Timer: Visible on Live site

About

Bio-Neuroscience convenes an outstanding mix of innovators, CEOs and decision-makers in CNS neuroscience drug development from the leading biotech companies, investors and pharma companies in the sector

Insight - Access - Engagement - Impact

Premier Gathering of Innovators

The one event which convenes a high-level, by-invitation, boutique gathering of thought leaders, innovators, CEOs and senior decision-makers from the leading stakeholders groups in CNS neuroscience drug development.

The business of CNS Neuroscience drug development.

Where CEOs and C-level executives of the hottest companies come together with industry leaders, decision-makers, patient organizations, funders and the leading investors in CNS neuroscience drug development to dive into the the issues that matter most to stakeholders.

Elevating Engagement and Collaboration

A unique level of sustained high-quality discussion, access, engagement and partnering in a truly unique and ideally curated event.

2026 EARLY REGISTRATION ENDS OCTOBER 31

Broadreach Neuro Summits - Participant Comments

I really enjoyed being part of Bio-Neuroscience, where I had the opportunity to exchange thoughts with key stakeholders from the neuroscience ecosystem. A key event in this booming field. I really look forward to the second edition.

Raúl Ruíz-Martin

Partner - Ysios Capital

I highly recommend Bio-Neuroscience 2024. I attended the inaugural conference, it was a unique, highly interactive meeting of key neuroscience stakeholders and I am looking forward to the next edition.

Mary Chamberlain-Tharp

Chief Business Officer - Neurmora

2026 EARLY REGISTRATION ENDS OCTOBER 31

Vision

Convening the full value chain to disrupt silos and curate highly interactive, multi-disciplinary, cross-industry, and multi-stakeholder discussions of opportunities, challenges, hurdles and ways forward.

Drive transformational connections, discussion and partnering for startups and growth companies.

Deliver insight, access, engagement and partnering to foster innovation and accelerate value creation.

Contribute to meaningful improvement in healthcare outcomes and positive impact for patients and society.

Get feedback and advice on your business, your objectives and your core challenges from leading innovators, investors and industry leaders in CNS neuroscience drug development.

Why Now?

Now is the time for CNS neuroscience drug development. We have entered a time when truly rational drug discovery and development is possible and where new discoveries, tools, technologies, biomarkers and insights enable improved development.

Investor and industry interest is booming, yet key challenges remain that can only be addressed by bringing together the leading translational research, clinicians, entrepreneurs, CEOs, CSOs and CMOs from the leading biotech companies, with relevant therapeutic area and business development heads from big pharma and large biotech, as well as the Partners and Directors heading neuroscience investment at the most active and important investment funds.

The 2024 pilot edition established Bio-Neuroscience as a unique, high-level and interactive summit providing participants exceptional value in terms of the experience, insight, access and impact. The 2025 edition firmly established Bio-Neuroscience as the key science - business - innovation - partnering & engagement meeting in the sector.

shutterstock_128316104 Thinking Impulses copy.jpg

Meet our Advisory Board

Advisory Board - 2026

Stacie Weninger

Executive Director - F-Prime Biomedical Research Initiative

Husseini K Manji, MD, FRCPC

Professor - Oxford University, Co-chair - UK Government Mental Health Mission

Kees Been

Chief Executive Officer - Kynexis Therapeutics Inc.

Arno de Wilde

Managing Director - EQT Life Sciences

Robert Thorne

Denali Fellow - Denali Therapeutics
Adjunct Associate Professor - University of Minnesota
President - International Brain Barriers Society (IBBS)

Claire Leurent

Managing Director - AbbVie Ventures

Andrea Soto Padilla

Business Development - Amsterdam UMC

Pieter van Bokhoven

Chief Scientific Officer - IXA Amsterdam Neuroscience UMC

Philip Scheltens

Head, Dementia Fund, Partner - EQT Life Sciences

Hakan Goker

Managing Director, Head of Healthcare & Life Sciences - M-Ventures

Juan Carlos Lopez

Managing Director - Haystack Science, formerly Chief Editor - Nature Medicine & Founding Editor - Nature Reviews Neuroscience

Sourav Kole

Investor & Board Member - Independent

Rita Balice-Gordon

Chief Executive Officer - Muna Therapeutics

Bruce Leuchter

President & CEO - Neurvati Neurosciences

Martien Kas

President - European College of NeuroPsychopharmacology (ECNP)

Christian J. Suojanen

Founder & CEO - Broadreach Global, Member of the Board - European Brain Foundation (EBF)

Advisory Board

Meet the Speakers - Here are a few of the speakers for 2026. Check back for the full lineup in September!

Proudly convening leading speakers and stakeholders from across the sector

Ben Deverman

Director, Vector Engineering, Stanley Center for Psychiatric Research - The Broad Institute of MIT and Harvard

Tarek Samad

Senior Vice President & Global Head of Research - Lundbeck

Richard Reschen

Director, Business Development & Licensing - MSD

Keno Gutierrez

General Partner - BioGeneration Ventures (BGV)

Alexander Natz

Secretary General - European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

António Portela

CEO - BIAL

Hugh Nuthall

Executive Director, Search & Evaluation, Neuroscience - Eli Lilly

Marcelo Bigal

President and Chief Executive Officer - Ventus Therapeutics

Andrew Steinsapir

Director, Gene Therapy Program Lead - Deefield Management, & Acting CTO, Apertura Gene Therapy

Joao Barbosa da Silva

Investor - re.Mind Capital

Giovanna Lalli

Director of Strategy & Operations - LifeArc

Maria Luisa Pineda

CEO & Co-Founder - Envisagenics

Jing Wang

Co-Founder & Chief Executive Officer - Myrobalan Therapeutics

Yael Weiss

CEO - Mahzi Therapeutics

Christian Thomsen

Global External CNS Research - Boehringer Ingelheim

Jacopo Andreose

CEO - Angelini Pharma S.p.A.

Kevin Sheridan

Joint Global Head of Healthcare Investment Banking - Jefferies LLC

Alex Bloom

Chief Technology Officer - AviadoBio

Opher Kornfeld

Director, Translational Research and Development - SPARK NS

Steffen Thirstrup

Chief Medical Officer - European Medicines Agency (or colleague)

Sven Pfeiffer

Partner, Strategic Advisory Group - PJT Partners

Pablo Sardi

Global Head, Rare & Neurologic Diseases Therapeutic Area - Sanofi

Eric Stewart

Senior Managing Director, Healthcare Mergers & Acquisitions - Leerink Partners

Who you'll meet

Over 2 days of high-level interactive discussion, networking and partnering with:

Industry Leaders

Industry decison-makers, Heads of Therapeutic Area, Scouting, Alliance Management, Business Development & Licensing, Strategy & Portfolio from pharma & large biotech.

Key Opinion Leaders

Key Opinion Leaders from research, clinical development & care, strategy, finance, business development, licensing, regulatory, market launch & M&A.

Founders & CEOs

Founders, CEOs & C-Level from the most innovative and hottest CNS neuroscience companies leading innovation & deals in the sector.

Government & NGOs

Public funding bodies, policy makers, public agencies, societies, associations & NGOs in neuroscience, agencies, regulatory bodies.

Investors

Managing Partners & Partners from the most active CNS Neuroscience investing VC funds, Managing Directors & Directors of the leading Corporate Venture, Private Equity and Family Office Funds, Foundations & more.

Patients

A selected group of leading patient driven companies, non profits, foundations, associations and charities focused on the development of novel therapies for patients.

Who's Coming?

Present

Presenting Companies

Benefit From

Pre-summit guidance and feedback on your deck.

A pre-summit dry-run presentation with feedback.

5 minute presentation followed by 5 minutes Q&A with an expert panel of relevant investors and industry: In front of the full audience in the plenary session - not off in some side room!

Join a curated selection of the most innovative, promising and high potential companies with potential to transform CNS neuroscience drug development & treatment. Selection is by excellence and potential, not by price tag! There is no cost to present beyond the regular startup or private company registration fees.

2026 Applications Open on 1 July 2025.

Your Poster in the networking area.

Post Pitch Meeting space in the main networking area to facilitate additional discussion in the networking break immediately following your session.

Over 2 Days of sustained engagement with the best network of innovators, investors, industry leaders & decision-makers in CNS neuroscience drug development.

Option to add an exclusive company exhibition stand. There is no requirement to sponsor or exhibit; these exist as separate options each and provide exceptional target market visibility with key investors, industry leaders and stakeholders. For avoidance of any confusion, exhibiting has no impact on selection for presentation.

Apply or Nominate to Pitch

Agenda & Program - 2025 Edition

Day 0 - February 25

15:00 - Registration & Networking Coffee

16:00 - Program Opens

18:00 - Welcome Reception

Day I - February 26

08:15 - Registration Opens

09:00 - Start of Program

13:15 - Networking Lunch

17:45 - End of Day & Networking Reception

Day II - February 27

08:15 - Registration Opens

09:00 - Start of Program

12:45 - Networking Lunch

16:15 - End of Day & Networking Reception

2025 Program

Venue

Bio-Neuroscience brings together an outstanding mix of leaders and decision-makers in CNS Neuroscience drug development.

Hotel Jakarta
Javakade 766, 1019 SH Amsterdam,
Netherlands

Bio-Neuroscience takes place at Hotel Jakarta, a sustainable modern hotel designed as a green oasis on the IJ river. The selection of the Hotel Jakarta Amsterdam as the new venue was made based on its central location, comfortable rooms and green atmosphere, and a setup which is well suited for the highly interactive but boutique interactive nature of Bio-Neuroscience, including improved plenary spaces, natural light, and increased networking space for business development and networking.

RESERVE YOUR HOTEL ROOM NOW.

The code BNEURO26 will provide participants a discount of 10% over the best available rate (at the moment of booking). This code is valid only for rooms booked in the period from the 20th of February until the 2nd of March.

Use the discount code BNEURO26 to book directly with the Hotel Jakarta link here.

HOTEL INFO

RESERVE HERE